Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BMG
|
|||
| Former ID |
DIB014351
|
|||
| Drug Name |
Amphetamine
|
|||
| Synonyms |
Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] | Approved | [1] | |
| Company |
PharmacoFore Inc
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C9H13N
|
|||
| Canonical SMILES |
CC(CC1=CC=CC=C1)N
|
|||
| InChI |
1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
|
|||
| InChIKey |
KWTSXDURSIMDCE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 300-62-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9717, 87765, 115861, 608004, 3249024, 5340423, 7978700, 8150111, 8151914, 10517686, 10524938, 10529136, 11336166, 11361405, 11462377, 11533323, 15297279, 24882028, 26746621, 31073245, 35804947, 36519861, 36651428, 39909068, 46506414, 47216854, 48110531, 48415560, 49855301, 49855567, 51091776, 53789505, 57321551, 57651795, 77830611, 85209571, 85756449, 99302079, 103164180, 103810791, 103918755, 104302255, 117525983, 125680154, 126677500, 127272449, 127272450, 127272451, 127272452, 127272453
|
|||
| ChEBI ID |
CHEBI:2679
|
|||
| ADReCS Drug ID | BADD_D00130 ; BADD_D00131 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Microbial Enzyme | Tyramine oxidase | |||
| Metabolic Effect | Increase activity | |||
| Description | Amphetamine can be metabolized by the tyramine oxidase of Escherichia coli, which results in the increase of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Trace amine-associated receptor-1 (TAAR1) | Target Info | Modulator | [1], [3], [4], [5], [6] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (s) signalling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jul;120(7):11206-11215. | |||
| REF 3 | Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. | |||
| REF 4 | Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J Neurochem. 2003 Jul;86(2):413-21. | |||
| REF 5 | Involvement of the alpha(1D)-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats. Neurotox Res. 2013 Aug;24(2):130-8. | |||
| REF 6 | Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice. Neurosci Lett. 2002 Dec 16;334(3):145-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.